
    
      The primary hypothesis of this study is that 18F-Fluciclovine PET/MRI imaging at two years
      following FCA will improve sensitivity for detection of in field recurrence of significant
      prostate cancer defined as any Gleason pattern 4 disease.

      The secondary hypothesis of this study is that 18F-Fluciclovine PET/MRI imaging at two years
      following FCA will improve sensitivity for detection of out of field recurrence of
      significant prostate cancer .
    
  